Related Experiment Videos
Development of polyetherurethane sheet embedded with powdered charcoal for use in hemoperfusion
Artificial Organs
|May 1, 1984
Summary
A novel polyetherurethane sheet with powdered charcoal (UPC) effectively removes bilirubin. This hemoperfusion material demonstrated superior in vitro adsorption and significant bilirubin reduction in jaundiced dogs.
Area of Science:
- Biomaterials Engineering
- Medical Device Development
- Hemoperfusion Technology
Background:
- Bilirubin overload is a critical issue in liver disease and jaundice.
- Existing hemoperfusion materials have limitations in efficiency and bilirubin adsorption.
- Development of advanced adsorbent materials is crucial for effective jaundice management.
Purpose of the Study:
- To develop and evaluate a novel polyetherurethane sheet embedded with powdered charcoal (UPC) for hemoperfusion.
- To assess the in vitro bilirubin adsorption capacity of the UPC material.
- To investigate the in vivo efficacy of UPC in reducing bilirubin levels in jaundiced animal models.
Main Methods:
- Fabrication of a 200-micron thick polyetherurethane sheet incorporating powdered charcoal with optimized pore and particle size (10-40 micron).
- In vitro adsorption experiments comparing UPC with bead-type charcoal and XAD-7 for bilirubin removal.
- In vivo hemoperfusion study using a UPC column in jaundiced dogs to measure bilirubin reduction.
Main Results:
- UPC demonstrated significantly higher in vitro bilirubin adsorption (14x and 6x) compared to bead-type charcoal and XAD-7, respectively.
- Hemoperfusion with UPC in jaundiced dogs resulted in effective bilirubin reduction.
- Maximum removal efficiencies of 78% for conjugated and 76% for unconjugated bilirubin were achieved in vivo.
Conclusions:
- The developed polyetherurethane sheet embedded with powdered charcoal (UPC) is a promising material for hemoperfusion.
- UPC exhibits superior bilirubin adsorption capabilities, offering a potential advancement in jaundice treatment.
- This material shows significant potential for clinical application in managing hyperbilirubinemia through hemoperfusion.